Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients.

ABSTRACT:

Background

Intravesical bacillus Calmette-Guérin (BCG) therapy is standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) but overall efficacy is low, and no reliable predictive biomarkers currently exist to refine patient selection. We performed genomic analysis on high-grade (HG) T1 NMIBCs to determine if response to therapy is predicted by certain mutational and/or expressional changes.

Methods

Patients with HG T1 NMIBC treated with induction BCG were stratified by response into durable and non-durable responders. Baseline tumor samples were subjected to targeted DNA sequencing and whole-exome RNAseq. Genomic variants differing significantly between response groups were analyzed using Ingenuity Pathway Analysis (IPA) software. Variant selection was ref

SUBMITTER: Sanders JA 

PROVIDER: S-EPMC8350238 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature